Fort Washington-based Vitae Pharmaceuticals and German drugmaker Boehringer Ingelheim are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.

Fort Washington-based Vitae Pharmaceuticals and German drugmaker Boehringer Ingelheim are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.